0001628280-24-032182.txt : 20240718 0001628280-24-032182.hdr.sgml : 20240718 20240718073735 ACCESSION NUMBER: 0001628280-24-032182 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240718 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240718 DATE AS OF CHANGE: 20240718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 241123710 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 2246676100 MAIL ADDRESS: STREET 1: 100 ABBOTT PARK ROAD CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 8-K 1 abt-20240718.htm 8-K abt-20240718
0000001800FALSENew York Stock ExchangeChicago Stock Exchange, Inc.00000018002024-07-182024-07-180000001800exch:XNYS2024-07-182024-07-180000001800exch:XCHI2024-07-182024-07-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
_______________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
July 18, 2024
Date of Report (Date of earliest event reported)
ABBOTT LABORATORIES
(Exact name of registrant as specified in charter)
_______________________________________________________

Illinois1-218936-0698440
(State or other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification  No.)
_______________________________________________________
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (224) 667-6100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class
Trading
Symbol(s)
Name of Each Exchange
on Which Registered
Common Shares, Without Par ValueABT
New York Stock Exchange
Chicago Stock Exchange, Inc.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 2.02    Results of Operations and Financial Condition
On July 18, 2024, Abbott Laboratories announced its results of operations for the second quarter 2024.
Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, a divestiture, restructuring actions, cost reduction initiatives, fair value adjustments to the contingent consideration related to business acquisitions, impairment charges related to intangible assets or equity investments, certain regulatory costs, tax benefits associated with specified items, net tax expense as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.
Item 9.01    Financial Statements and Exhibits
Exhibit No.Exhibit
104Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ABBOTT LABORATORIES
Date: July 18, 2024 By:/s/ Philip P. Boudreau
Philip P. Boudreau
Executive Vice President, Finance and Chief Financial Officer

 EX-99.1 2 abt-2024q2xexhibitx991.htm EX-99.1 Document

Exhibit 99.1 9.1
abbottlogoa.jpg
  News Release

Abbott Reports Second-Quarter 2024 Results and Raises
Full-Year Guidance

–Sales of $10.4 billion driven by strong underlying base business performance
–Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical Devices
–Continues to strengthen portfolio with new product approvals
ABBOTT PARK, Ill., July 18, 2024 — Abbott today announced financial results for the second quarter ended June 30, 2024.

•Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items.
•Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS of $4.61 to $4.71.
•Abbott narrowed its full-year 2024 organic sales growth guidance range, excluding COVID-19 testing-related sales, to 9.5% to 10.0%, which represents an increase at the midpoint of the range2.
•In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of the Esprit™ below-the-knee (BTK) system, a breakthrough innovation for people living with peripheral artery disease. This system is designed to keep arteries open and deliver a drug to support vessel healing prior to completely dissolving.
•In June, Abbott announced U.S. FDA clearance for two new over-the-counter continuous glucose monitoring systems — Lingo™ and Libre Rio™, which are based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology3.
•In June, Abbott obtained CE Mark for its AVEIR® dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms.
•During the first half of 2024, Abbott announced 10 new growth opportunities coming from the company's highly productive R&D pipeline. These include a combination of new product approvals and new treatment indications.

"We achieved another quarter of strong growth in our underlying base business," said Robert B. Ford, chairman and chief executive officer, Abbott. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance."
-- more -- 
Page 1 of 20

SECOND-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, the impact of discontinuing the ZonePerfect® product line in the Nutrition business, and the impact of the acquisition of Cardiovascular Systems, Inc. (CSI) during the first year post-acquisition, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.


Second Quarter 2024 Results (2Q24)
Sales 2Q24 ($ in millions)
Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
U.S.3,934 933 812 — 2,185 
International6,443 1,217 1,383 1,294 2,549 
Total reported10,377 2,150 2,195 1,294 4,734 
% Change vs. 2Q23
U.S.4.7 6.0 (15.5)n/a14.2 
International3.6 1.7 1.9 0.6 7.0 
Total reported4.0 3.5 (5.3)0.6 10.2 
Impact of foreign exchange(3.5)(3.6)(3.8)(7.5)(2.2)
Impact of business exit and acquisition*
0.1 (0.4)— — 0.3 
Organic7.4 7.5 (1.5)8.1 12.1 
Impact of COVID-19 testing sales (4)
(1.9)— (7.4)— — 
Organic (excluding COVID-19 tests)9.3 7.5 5.9 8.1 12.1 
    U.S.9.0 6.9 (0.3)n/a13.5 
    International9.4 7.9 9.5 8.1 10.9 

First Half 2024 Results (1H24)
Sales 1H24 ($ in millions)
Total CompanyNutritionDiagnosticsEstablished PharmaceuticalsMedical Devices
U.S.7,780 1,811 1,743 — 4,219 
International12,561 2,407 2,666 2,520 4,968 
Total reported20,341 4,218 4,409 2,520 9,187 
% Change vs. 1H23
U.S.1.2 7.0 (24.1)n/a14.3 
International4.3 2.4 (1.6)1.8 10.3 
Total reported3.1 4.3 (11.9)1.8 12.1 
Impact of foreign exchange(3.2)(3.1)(2.9)(9.0)(1.7)
Impact of business exit and acquisition*
0.2 (0.2)— — 0.7 
Organic6.1 7.6 (9.0)10.8 13.1 
Impact of COVID-19 testing sales (4)
(3.9)— (14.7)— — 
Organic (excluding COVID-19 tests)10.0 7.6 5.7 10.8 13.1 
    U.S.9.5 7.5 3.3 n/a12.8 
    International10.3 7.7 7.1 10.8 13.4 
Refer to page 16 for a reconciliation of adjusted historical revenue to reported revenue.

*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024 and the acquisition of CSI on April 27, 2023. Organic sales growth excludes the impact of the acquired business from January through April 2024.
-- more --
Page 2 of 20


Nutrition

Second Quarter 2024 Results (2Q24)

Sales 2Q24 ($ in millions)
TotalPediatricAdult
U.S.933 564 369 
International1,217 495 722 
Total reported2,150 1,059 1,091 
% Change vs. 2Q23
U.S.6.0 11.3 (1.2)
International1.7 (4.4)6.4 
Total reported3.5 3.4 3.7 
Impact of foreign exchange(3.6)(1.6)(5.4)
Impact of business exit*
(0.4)— (0.8)
Organic7.5 5.0 9.9 
    U.S.6.9 11.3 0.8 
    International7.9 (1.0)14.7 
Worldwide Nutrition sales increased 3.5 percent on a reported basis and 7.5 percent on an organic basis in the second quarter.
In Pediatric Nutrition, global sales increased 3.4 percent on a reported basis and 5.0 percent on an organic basis. Sales in the U.S. reflect continued market share gains in the infant formula business.
In Adult Nutrition, global sales increased 3.7 percent on a reported basis and 9.9 percent on an organic basis, which was led by strong growth of Ensure®, Abbott's market-leading complete and balanced nutrition brand.


First Half 2024 Results (1H24)

Sales 1H24 ($ in millions)
TotalPediatricAdult
U.S.1,811 1,078 733 
International2,407 990 1,417 
Total reported4,218 2,068 2,150 
% Change vs. 1H23
U.S.7.0 11.6 0.8 
International2.4 0.7 3.6 
Total reported4.3 6.1 2.6 
Impact of foreign exchange(3.1)(1.5)(4.6)
Impact of business exit*(0.2)— (0.4)
Organic7.6 7.6 7.6 
    U.S.7.5 11.6 1.9 
    International7.7 3.7 10.5 



*Reflects the impact of discontinuing the ZonePerfect® product line. This action was initiated in March 2024.

-- more --
Page 3 of 20


Diagnostics

Second Quarter 2024 Results (2Q24)
Sales 2Q24 ($ in millions)
TotalCore LaboratoryMolecularPoint of CareRapid Diagnostics
U.S.812 327 33 107 345 
International1,383 1,002 94 49 238 
Total reported2,195 1,329 127 156 583 
% Change vs. 2Q23
U.S.(15.5)5.1 (22.5)8.1 (32.1)
International1.9 2.1 (4.9)14.1 2.1 
Total reported(5.3)2.8 (10.3)9.9 (21.3)
Impact of foreign exchange(3.8)(5.8)(0.9)(0.1)(1.5)
Organic(1.5)8.6 (9.4)10.0 (19.8)
Impact of COVID-19 testing sales (4)
(7.4)(0.2)(3.8)— (20.2)
Organic (excluding COVID-19 tests)5.9 8.8 (5.6)10.0 0.4 
    U.S.(0.3)5.3 (19.0)8.1 (6.6)
    International9.5 9.9 — 14.5 11.0 

As expected, Diagnostics sales growth in the second quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales4. Worldwide COVID-19 testing sales were $102 million in the second quarter of 2024 compared to $263 million in the second quarter of the prior year.

Excluding COVID-19 testing-related sales, global Diagnostics sales increased 1.8 percent on a reported basis and 5.9 percent on an organic basis.

Excluding COVID-19 testing-related sales, global Core Laboratory Diagnostics sales increased 3.0 percent on a reported basis and 8.8 percent on an organic basis, led by continued strong adoption of Abbott's Alinity® family of diagnostics systems and testing portfolios.


First Half 2024 Results (1H24)
Sales 1H24 ($ in millions)
TotalCore LaboratoryMolecularPoint of CareRapid Diagnostics
U.S.1,743 637 75 205 826 
International2,666 1,897 181 90 498 
Total reported4,409 2,534 256 295 1,324 
% Change vs. 1H23
U.S.(24.1)6.2 (16.3)6.9 (41.6)
International(1.6)1.2 (8.8)6.9 (9.7)
Total reported(11.9)2.4 (11.1)6.9 (32.7)
Impact of foreign exchange(2.9)(4.9)(0.6)— (1.1)
Organic(9.0)7.3 (10.5)6.9 (31.6)
Impact of COVID-19 testing sales (4)
(14.7)(0.3)(7.3)— (34.6)
Organic (excluding COVID-19 tests)5.7 7.6 (3.2)6.9 3.0 
    U.S.3.3 6.5 (6.7)6.9 0.3 
    International7.1 7.9 (1.8)7.1 7.1 



-- more --
Page 4 of 20


Established Pharmaceuticals

Second Quarter 2024 Results (2Q24)
Sales 2Q24 ($ in millions)
TotalKey Emerging MarketsOther
U.S.— — — 
International1,294 988 306 
Total reported1,294 988 306 
% Change vs. 2Q23
U.S.n/an/an/a
International0.6 (0.2)3.1 
Total reported0.6 (0.2)3.1 
Impact of foreign exchange(7.5)(9.0)(2.6)
Organic 8.1 8.8 5.7 
    U.S.n/an/an/a
    International8.1 8.8 5.7 

Established Pharmaceuticals sales increased 0.6 percent on a reported basis and 8.1 percent on an organic basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies decreased 0.2 percent on a reported basis and increased 8.8 percent on an organic basis, led by growth in several geographies and therapeutic areas, including cardiometabolic, gastroenterology, and central nervous system/pain management.


First Half 2024 Results (1H24)
Sales 1H24 ($ in millions)
TotalKey Emerging MarketsOther
U.S.— — — 
International2,520 1,916 604 
Total reported2,520 1,916 604 
% Change vs. 1H23
U.S.n/an/an/a
International1.8 0.7 5.3 
Total reported1.8 0.7 5.3 
Impact of foreign exchange(9.0)(11.3)(1.6)
Organic 10.8 12.0 6.9 
    U.S.n/an/an/a
    International10.8 12.0 6.9 











-- more --
Page 5 of 20


Medical Devices

Second Quarter 2024 Results (2Q24)
Sales 2Q24 ($ in millions)
TotalRhythm ManagementElectro-
physiology		Heart FailureVascularStructural HeartNeuro-modulationDiabetes Care
U.S.2,185 292 287 244 275 258 192 637 
International2,549 315 340 77 449 306 51 1,011 
Total reported4,734 607 627 321 724 564 243 1,648 
% Change vs. 2Q23
U.S.14.2 8.5 16.8 7.7 4.3 17.9 3.7 26.3 
International7.0 0.4 10.5 11.4 (0.4)9.4 21.7 10.0 
Total reported10.2 4.2 13.3 8.6 1.3 13.2 7.0 15.8 
Impact of foreign exchange(2.2)(1.7)(3.4)(0.3)(2.0)(2.4)(1.2)(2.4)
Impact of acquisition*0.3 — — — 2.1 — — — 
Organic 12.1 5.9 16.7 8.9 1.2 15.6 8.2 18.2 
    U.S.13.5 8.5 16.8 7.7 (0.8)17.9 3.7 26.3 
    International10.9 3.7 16.7 12.8 2.5 13.8 28.4 13.7 

Worldwide Medical Devices sales increased 10.2 percent on a reported basis and 12.1 percent on an organic basis in the second quarter, including double-digit organic growth in both the U.S. and internationally.

Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart. Several recently launched products and new indications contributed to the strong performance, including Amplatzer® Amulet®, Navitor®, TriClip®, and AVEIR®.

In Electrophysiology, sales grew 13.3 percent on a reported basis and 16.7 percent on an organic basis, which included double-digit growth in catheters and cardiac mapping-related products, and double-digit growth in all major geographic regions.

In Diabetes Care, FreeStyle Libre sales were $1.6 billion, which represents sales growth of 18.4 percent on a reported basis and 20.4 percent on an organic basis.


First Half 2024 Results (1H24)
Sales 1H24 ($ in millions)
TotalRhythm ManagementElectro-
physiology		Heart FailureVascularStructural HeartNeuro-modulationDiabetes Care
U.S.4,219 563 556 481 529 491 373 1,226 
International4,968 606 658 145 884 588 96 1,991 
Total reported9,187 1,169 1,214 626 1,413 1,079 469 3,217 
% Change vs. 1H23
U.S.14.3 6.6 15.0 8.2 9.8 14.4 9.6 24.6 
International10.3 4.4 14.4 9.7 4.1 10.9 15.9 13.6 
Total reported12.1 5.4 14.7 8.6 6.1 12.5 10.9 17.6 
Impact of foreign exchange(1.7)(1.3)(2.8)(0.1)(1.5)(1.8)(1.6)(1.8)
Impact of acquisition*0.7 — — — 4.3 — — — 
Organic 13.1 6.7 17.5 8.7 3.3 14.3 12.5 19.4 
    U.S.12.8 6.6 15.0 8.2 (1.3)14.4 9.6 24.6 
    International13.4 6.8 19.6 10.1 6.0 14.3 24.1 16.5 

*Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.

-- more --
Page 6 of 20


ABBOTT'S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.30 to $3.40. Abbott forecasts specified items for the full-year 2024 of $1.31 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.61 to $4.71 for the full-year 2024.

Abbott projects third-quarter 2024 diluted earnings per share under GAAP of $0.85 to $0.89. Abbott forecasts specified items for the third-quarter 2024 of $0.33 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $1.18 to $1.22 for the third quarter 2024.
ABBOTT DECLARES 402ND CONSECUTIVE QUARTERLY DIVIDEND
On June 14, 2024, the board of directors of Abbott declared the company's quarterly dividend of $0.55 per share. Abbott's cash dividend is payable Aug. 15, 2024, to shareholders of record at the close of business on July 15, 2024.

Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.


About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.
-- more --
Page 7 of 20


— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2023, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Abbott Financial:
Michael Comilla, 224-668-1872
Tamika LeBean, 224-399-5082
Ryan Aliff, 224-667-2299
Abbott Media:
Karen Twigg May, 224-668-2681
Kate Dyer, 224-668-9965
1In the second quarter of 2024, total worldwide sales were $10.377 billion and COVID-19 testing-related sales were $102 million. In the second quarter of 2023, total worldwide sales were $9.978 billion and COVID-19 testing-related sales were $263 million.

2Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for COVID-19 tests.

3Data on file. Abbott Diabetes Care.

4Diagnostic sales and COVID-19 testing-related sales in 2024 and 2023 are summarized below:
Sales 2Q24COVID Tests Sales 2Q24
($ in millions)U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics812 1,383 2,195 69 33 102 
Core Laboratory327 1,002 1,329 1 1 2 
Molecular33 94 127 2 1 3 
Rapid Diagnostics345 238 583 66 31 97 
Sales 2Q23COVID Tests Sales 2Q23
($ in millions)U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics961 1,356 2,317 216 47 263 
Core Laboratory311 982 1,293 2 3 5 
Molecular43 98 141 4 4 8 
Rapid Diagnostics508 233 741 210 40 250 

Sales 1H24COVID Tests Sales 1H24
($ in millions)U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics1,743 2,666 4,409 222 84 306 
Core Laboratory637 1,897 2,534 2 3 5 
Molecular75 181 256 5 2 7 
Rapid Diagnostics826 498 1,324 215 79 294 
Sales 1H23COVID Tests Sales 1H23
($ in millions)U.S.Int'lTotalU.S.Int'lTotal
Total Diagnostics2,296 2,709 5,005 824 169 993 
Core Laboratory600 1,875 2,475 4 7 11 
Molecular90 198 288 14 14 28 
Rapid Diagnostics1,414 552 1,966 806 148 954 

-- more --
Page 8 of 20


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
Second Quarter Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)




2Q242Q23% Change
Net Sales$10,377$9,9784.0 
Cost of products sold, excluding amortization expense4,603 4,483 2.7 
Amortization of intangible assets471 498 (5.6)
Research and development698 715 (2.3)
Selling, general, and administrative2,936 2,740 7.1 
Total Operating Cost and Expenses8,708 8,436 3.2 
Operating Earnings1,669 1,542 8.2 
Interest expense, net58 61 (5.1)
Net foreign exchange (gain) loss(6)21 n/m
Other (income) expense, net10 (176)n/m
Earnings before taxes1,607 1,636 (1.8)
Taxes on earnings305 261 17.1 1)
Net Earnings$1,302$1,375(5.3)
Net Earnings excluding Specified Items, as described below$2,003$1,8935.8 2)
Diluted Earnings per Common Share$0.74$0.78(5.1)
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$1.14$1.085.6 2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,751 1,750 


NOTES:
See tables on page 13 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 9 of 20


1)2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2023 Taxes on Earnings includes the recognition of approximately $40 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $701 million, or $0.40 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.

2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $518 million, or $0.30 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.
-- more --
Page 10 of 20


Abbott Laboratories and Subsidiaries
Condensed Consolidated Statement of Earnings
First Half Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)




1H241H23% Change
Net Sales$20,341$19,7253.1 
Cost of products sold, excluding amortization expense9,066 8,814 2.9 
Amortization of intangible assets943 989 (4.7)
Research and development1,382 1,369 0.9 
Selling, general, and administrative5,895 5,502 7.1 
Total Operating Cost and Expenses17,286 16,674 3.7 
Operating Earnings3,055 3,051 0.2 
Interest expense, net119 113 5.6 
Net foreign exchange (gain) loss(6)27 n/m
Other (income) expense, net(101)(287)n/m
Earnings before taxes3,043 3,198 (4.8)
Taxes on earnings516 505 2.2 1)
Net Earnings$2,527$2,693(6.2)
Net Earnings excluding Specified Items, as described below$3,732$3,7080.7 2)
Diluted Earnings per Common Share$1.44$1.53(5.9)
Diluted Earnings per Common Share,
excluding Specified Items, as described below
$2.12$2.110.5 2)
Average Number of Common Shares Outstanding
Plus Dilutive Common Stock Options
1,750 1,751 



NOTES:
See tables on page 14 for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following page.
-- more --
Page 11 of 20


1)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2023 Taxes on Earnings includes the recognition of approximately $62 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.205 billion, or $0.68 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and a divestiture, and other net expenses.

2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.015 billion, or $0.58 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses.

-- more --
Page 12 of 20


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
Second Quarter Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
2Q24
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$471 $(471)$— 
Gross Margin
5,303 506 5,809 
R&D
698 (41)657 
SG&A
2,936 (57)2,879 
Other (income) expense, net
10 (145)(135)
Earnings before taxes
1,607 749 2,356 
Taxes on Earnings
305 48 353 
Net Earnings
1,302 701 2,003 
Diluted Earnings per Share
$0.74 $0.40 $1.14 

Specified items reflect intangible amortization expense of $471 million and other net expenses of $278 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 17 for additional details regarding specified items.
2Q23
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$498 $(498)$— 
Gross Margin
4,997 529 5,526 
R&D
715 (72)643 
SG&A
2,740 (22)2,718 
Other (income) expense, net
(176)57 (119)
Earnings before taxes
1,636 566 2,202 
Taxes on Earnings
261 48 309 
Net Earnings
1,375 518 1,893 
Diluted Earnings per Share
$0.78 $0.30 $1.08 

Specified items reflect intangible amortization expense of $498 million and other net expenses of $68 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See page 18 for additional details regarding specified items.
-- more --
Page 13 of 20


Abbott Laboratories and Subsidiaries
Non-GAAP Reconciliation of Financial Information
First Half Ended June 30, 2024 and 2023
(in millions, except per share data)
(unaudited)
1H24
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$943 $(943)$— 
Gross Margin
10,332 1,024 11,356 
R&D
1,382 (62)1,320 
SG&A
5,895 (91)5,804 
Other (income) expense, net
(101)(171)(272)
Earnings before taxes
3,043 1,348 4,391 
Taxes on Earnings
516 143 659 
Net Earnings
2,527 1,205 3,732 
Diluted Earnings per Share
$1.44 $0.68 $2.12 

Specified items reflect intangible amortization expense of $943 million and other net expenses of $405 million associated with restructuring actions, acquisitions, a divestiture and other net expenses. See page 19 for additional details regarding specified items.
1H23
As
Reported (GAAP)		Specified ItemsAs
Adjusted
Intangible Amortization
$989 $(989)$— 
Gross Margin
9,922 1,049 10,971 
R&D
1,369 (98)1,271 
SG&A
5,502 (24)5,478 
Other (income) expense, net
(287)57 (230)
Earnings before taxes
3,198 1,114 4,312 
Taxes on Earnings
505 99 604 
Net Earnings
2,693 1,015 3,708 
Diluted Earnings per Share
$1.53 $0.58 $2.11 

Specified items reflect intangible amortization expense of $989 million and other net expenses of $125 million associated with restructuring actions, costs associated with acquisitions and other expenses. See page 20 for additional details regarding specified items.









-- more --
Page 14 of 20


A reconciliation of the second-quarter tax rates for 2024 and 2023 is shown below:
2Q24
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$1,607 $305 19.0 %1)
Specified items749 48 
Excluding specified items$2,356 $353 15.0 %
2Q23
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$1,636 $261 15.9 %2)
Specified items566 48 
Excluding specified items$2,202 $309 14.0 %
1)2024 Taxes on Earnings includes the recognition of approximately $25 million of net tax expense as a result of the resolution of various tax positions related to prior years.

2)2023 Taxes on Earnings includes the recognition of approximately $40 million of net tax expense as a result of the resolution of various tax positions related to prior years.

A reconciliation of the year-to-date tax rates for 2024 and 2023 is shown below:
1H24
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$3,043 $516 17.0 %3)
Specified items1,348 143 
Excluding specified items$4,391 $659 15.0 %
1H23
($ in millions)Pre-Tax
Income		Taxes on
Earnings		Tax
Rate
As reported (GAAP)$3,198 $505 15.8 %4)
Specified items1,114 99 
Excluding specified items$4,312 $604 14.0 %

3)2024 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense as a result of the resolution of various tax positions related to prior years.

4)2023 Taxes on Earnings includes the recognition of approximately $62 million of net tax expense as a result of the resolution of various tax positions related to prior years.


-- more --
Page 15 of 20


Abbott Laboratories and Subsidiaries
Non-GAAP Revenue Reconciliation
Second Quarter and First Half Ended June 30, 2024 and 2023
($ in millions)
(unaudited)
2Q242Q23% Change vs. 2Q23
Non-GAAP
Abbott ReportedImpact of acquisition (a)Impact from business exit (b)Adjusted RevenueAbbott ReportedImpact from business exit (b)Adjusted RevenueReportedAdjustedOrganic
Total Company10,377 (15)(8)10,354 9,978 (15)9,963 4.0 3.9 7.4 
U.S.3,934 (13)(8)3,913 3,758 (15)3,743 4.7 4.6 4.6 
Intl6,443 (2)— 6,441 6,220 — 6,220 3.6 3.5 9.2 
Total Nutrition2,150 — (8)2,142 2,076 (15)2,061 3.5 3.9 7.5 
U.S.933 — (8)925 881 (15)866 6.0 6.9 6.9 
Intl1,217 — — 1,217 1,195 — 1,195 1.7 1.7 7.9 
Adult Nutrition1,091 — (8)1,083 1,052 (15)1,037 3.7 4.5 9.9 
U.S.369 — (8)361 374 (15)359 (1.2)0.8 0.8 
Intl722 — — 722 678 — 678 6.4 6.4 14.7 
Total Medical Devices4,734 (15)— 4,719 4,295 — 4,295 10.2 9.9 12.1 
U.S.2,185 (13)— 2,172 1,913 — 1,913 14.2 13.5 13.5 
Intl2,549 (2)— 2,547 2,382 — 2,382 7.0 7.0 10.9 
Vascular724 (15)— 709 715 — 715 1.3 (0.8)1.2 
U.S.275 (13)— 262 264 — 264 4.3 (0.8)(0.8)
Intl449 (2)— 447 451 — 451 (0.4)(0.6)2.5 
1H241H23% Change vs. 1H23
Non-GAAP
Abbott ReportedImpact of acquisition (a)Impact from business exit (b)Adjusted RevenueAbbott ReportedImpact from business exit (b)Adjusted RevenueReportedAdjustedOrganic
Total Company20,341 (57)(8)20,276 19,725 (15)19,710 3.1 2.9 6.1 
U.S.7,780 (53)(8)7,719 7,686 (15)7,671 1.2 0.6 0.6 
Intl12,561 (4)— 12,557 12,039 — 12,039 4.3 4.3 9.6 
Total Nutrition4,218 — (8)4,210 4,043 (15)4,028 4.3 4.5 7.6 
U.S.1,811 — (8)1,803 1,693 (15)1,678 7.0 7.5 7.5 
Intl2,407 — — 2,407 2,350 — 2,350 2.4 2.4 7.7 
Adult Nutrition2,150 — (8)2,142 2,095 (15)2,080 2.6 3.0 7.6 
U.S.733 — (8)725 727 (15)712 0.8 1.9 1.9 
Intl1,417 — — 1,417 1,368 — 1,368 3.6 3.6 10.5 
Total Medical Devices9,187 (57)— 9,130 8,195 — 8,195 12.1 11.4 13.1 
U.S.4,219 (53)— 4,166 3,691 — 3,691 14.3 12.8 12.8 
Intl4,968 (4)— 4,964 4,504 — 4,504 10.3 10.2 13.4 
Vascular1,413 (57)— 1,356 1,332 — 1,332 6.1 1.8 3.3 
U.S.529 (53)— 476 482 — 482 9.8 (1.3)(1.3)
Intl884 (4)— 880 850 — 850 4.1 3.6 6.0 

(a) Abbott completed the acquisition of CSI on April 27, 2023. For purposes of calculating organic sales growth, the impact from this acquired business has been excluded from January through April 2024.
(b) Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.

-- more --
Page 16 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2024
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$1 $32 $471 $2 $506 
R&D(1)1 — (41)(41)
SG&A(11)(10)— (36)(57)
Other (income) expense, net(147)— — 2 (145)
Earnings before taxes$160 $41 $471 $77 749 
Taxes on Earnings (d)48 
Net Earnings$701 
Diluted Earnings per Share$0.40 
The table above provides additional details regarding the specified items described on page 13.

a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and an intangible asset impairment charge.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.



-- more --
Page 17 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
Second Quarter Ended June 30, 2023
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$7 $11 $498 $13 $529 
R&D(8)7 — (71)(72)
SG&A(17)(2)— (3)(22)
Other (income) expense, net47 — — 10 57 
Earnings before taxes$(15)$6 $498 $77 566 
Taxes on Earnings (d)48 
Net Earnings$518 
Diluted Earnings per Share$0.30 

The table above provides additional details regarding the specified items described on page 13.
a)Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. These costs were more than offset by fair value adjustments to contingent consideration related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.



















-- more --
Page 18 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2024
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$2 $74 $943 $5 $1,024 
R&D(4)(1)— (57)(62)
SG&A(25)(19)— (47)(91)
Other (income) expense, net(135)— — (36)(171)
Earnings before taxes$166 $94 $943 $145 1,348 
Taxes on Earnings (d)143 
Net Earnings$1,205 
Diluted Earnings per Share$0.68 
The table above provides additional details regarding the specified items described on page 14.

a)Includes the loss on the sale of a non-core business. Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.




















-- more --
Page 19 of 20


Abbott Laboratories and Subsidiaries
Details of Specified Items
First Half Ended June 30, 2023
(in millions, except per share data)
(unaudited)

Acquisition or
Divestiture-
related (a)		Restructuring
and Cost
Reduction
Initiatives (b)		Intangible
Amortization		Other (c)Total
Specifieds
Gross Margin$12 $32 $989 $16 $1,049 
R&D(12)8 — (94)(98)
SG&A(21)(6)— 3 (24)
Other (income) expense, net41 — — 16 57 
Earnings before taxes$4 $30 $989 $91 1,114 
Taxes on Earnings (d)99 
Net Earnings$1,015 
Diluted Earnings per Share$0.58 

The table above provides additional details regarding the specified items described on page 14.
a)Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. These costs were partially offset by fair value adjustments to contingent consideration related to business acquisitions.
b)Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments.
d)Reflects the net tax benefit associated with the specified items and tax expense as a result of the resolution of various tax positions related to prior years.
###
Page 20 of 20
 EX-101.SCH 3 abt-20240718.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 abt-20240718_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 abt-20240718_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Listings, Exchange [Axis] Entity Listings, Exchange [Axis] NYSE CHICAGO, INC. NYSE CHICAGO, INC. [Member] Security Exchange Name Security Exchange Name Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Cover [Abstract] City Area Code City Area Code Amendment Flag Amendment Flag Entity Tax Identification Number Entity Tax Identification Number Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company NEW YORK STOCK EXCHANGE, INC. NEW YORK STOCK EXCHANGE, INC. [Member] Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Document Information [Line Items] Document Information [Line Items] Document Information [Table] Document Information [Table] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications Local Phone Number Local Phone Number Exchange [Domain] Exchange [Domain] Title of 12(b) Security Title of 12(b) Security Document Period End Date Document Period End Date Document Type Document Type EX-101.PRE 6 abt-20240718_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 abbottlogoa.jpg begin 644 abbottlogoa.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 18, 2024
Document Information [Line Items]  
Document Type 8-K
Document Period End Date Jul. 18, 2024
Entity Registrant Name ABBOTT LABORATORIES
Entity Incorporation, State or Country Code IL
Entity File Number 1-2189
Entity Tax Identification Number 36-0698440
Entity Address, Address Line One 100 Abbott Park Road
Entity Address, City or Town Abbott Park
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60064-6400
City Area Code 224
Local Phone Number 667-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0000001800
Amendment Flag false
NYSE CHICAGO, INC.  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name CHX
NEW YORK STOCK EXCHANGE, INC.  
Document Information [Line Items]  
Title of 12(b) Security Common Shares, Without Par Value
Trading Symbol ABT
Security Exchange Name NYSE
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 3 22 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://abbott.com/role/Cover Cover Cover 1 false false All Reports Book All Reports abt-20240718.htm abt-20240718.xsd abt-20240718_def.xml abt-20240718_lab.xml abt-20240718_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abt-20240718.htm": { "nsprefix": "abt", "nsuri": "http://abbott.com/20240718", "dts": { "inline": { "local": [ "abt-20240718.htm" ] }, "schema": { "local": [ "abt-20240718.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd" ] }, "definitionLink": { "local": [ "abt-20240718_def.xml" ] }, "labelLink": { "local": [ "abt-20240718_lab.xml" ] }, "presentationLink": { "local": [ "abt-20240718_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 27 }, "report": { "R1": { "role": "http://abbott.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240718.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "abt-20240718.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityListingsExchangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingsExchangeAxis", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Listings, Exchange [Axis]", "label": "Entity Listings, Exchange [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_ExchangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ExchangeDomain", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange [Domain]", "label": "Exchange [Domain]", "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "exch_XCHI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XCHI", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "NYSE CHICAGO, INC.", "label": "NYSE CHICAGO, INC. [Member]" } } }, "auth_ref": [] }, "exch_XNYS": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2024", "localname": "XNYS", "presentation": [ "http://abbott.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "NEW YORK STOCK EXCHANGE, INC.", "label": "NEW YORK STOCK EXCHANGE, INC. [Member]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001628280-24-032182-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-032182-xbrl.zip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end XML 19 abt-20240718_htm.xml IDEA: XBRL DOCUMENT 0000001800 2024-07-18 2024-07-18 0000001800 exch:XNYS 2024-07-18 2024-07-18 0000001800 exch:XCHI 2024-07-18 2024-07-18 0000001800 false NYSE CHX 8-K 2024-07-18 ABBOTT LABORATORIES IL 1-2189 36-0698440 100 Abbott Park Road Abbott Park IL 60064-6400 224 667-6100 false false false false Common Shares, Without Par Value Common Shares, Without Par Value ABT ABT NYSE CHX false